Evolution of the Average Target: Opus Genetics, Inc.

Evolution of the Target Price: Opus Genetics, Inc.

Changes in Analyst Recommendations: Opus Genetics, Inc.

9fc82585bc88091fa2f87c8c3d38.mxzxe6pJ5CfmyeAOFo7fHXLrZnSoUi25k_1UP-R7mk0.qkS1OtB8lFHV-IJLXs--azaAERf3DWvXx549bNUO1yfMb8FPzhDVTdWuiw~a9fd262ab40eef0c83925e62112811f0
06-18 Chardan Raises Price Target on Opus Genetics to $13 From $11, Keeps Buy Rating MT
06-04 Guggenheim Initiates Opus Genetics at Buy With $16 Price Target MT
05-21 Leerink Partners Initiates Opus Genetics at Outperform With $10 Price Target MT
04-30 B. Riley Adjusts Opus Genetics Price Target to $10 From $9, Maintains Buy Rating MT
03-30 Cantor Fitzgerald Initiates Opus Genetics at Overweight With $15 Price Target MT
03-16 Oppenheimer Initiates Opus Genetics at Outperform With $10 Price Target MT
03-12 Wedbush Raises Price Target on Opus Genetics to $10 From $8, Keeps Outperform Rating MT
03-12 Chardan Raises Price Target on Opus Genetics to $11 From $9, Keeps Buy Rating MT
12-10 B. Riley Initiates Opus Genetics at Buy With $9 Price Target MT
24-03-20 Alliance Global Partners Cuts Price Target on Ocuphire Pharma to $20 From $24, Maintains Buy Rating MT
23-05-15 Cantor Fitzgerald Cuts Ocuphire Pharma's Price Target to $17 From $24, Maintains Overweight Rating MT
23-01-26 HC Wainwright Adjusts Ocuphire Pharma's Price Target to $20 From $26, Keeps Buy Rating MT
21-11-24 HC Wainwright Starts Ocuphire Pharma at Buy With $26 Price Target MT
21-04-05 OCUPHIRE PHARMA : Alliance Global Securities Initiates Coverage on Ocuphire Pharma With Buy Rating, $25 Price Target MT
21-03-29 OCUPHIRE PHARMA : JonesTrading Starts Ocuphire Pharma at Buy With $20 Price Target MT
21-03-15 OCUPHIRE PHARMA : Cantor Fitzgerald Adjusts Ocuphire Pharma PT to $20 From $15, Maintains Overweight Rating MT
21-02-10 OCUPHIRE PHARMA : Canaccord Starts Ocuphire Pharma at Buy with $22 Price Target MT
20-11-20 OCUPHIRE PHARMA : Cantor Fitzgerald Initiates Ocuphire Pharma at Overweight With $15 Price Target MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+163.89%
+1.2%
+1.12%
+0.41%
+6.8%
+16.62%
-1.01%
-1.05%
-1.55%
+23.22%
Average +20.96%
Weighted average by Cap. +3.38%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
4.050USD
Average target price
10.56USD
Spread / Average Target
+160.63%
High Price Target
16.00USD
Spread / Highest target
+295.06%
Low Price Target
8.000USD
Spread / Lowest Target
+97.53%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Chardan Research
Guggenheim
Leerink Partners
B. Riley
Cantor Fitzgerald
Oppenheimer
Wedbush
Alliance Global Partners
HC Wainwright
JonesTrading Institutional Services
Canaccord Genuity
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
4.050USD
Average target price
10.56USD
Spread / Average Target
+160.63%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IRD Stock
  4. Consensus Opus Genetics, Inc.